A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer

NCT00632541 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

18

Enrollment

OTHER

Sponsor class

Stopped Significant Toxicities Experienced

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Sorafenib
DRUG: Bevacizumab
OTHER: Imaging

Sponsor

Hoosier Cancer Research Network

Collaborators

[object Object]
[object Object]
[object Object]